SCHEDULE: Nantahala Capital Reports 0% Stake in Quince Therapeutics

Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, have reported a 0.00% beneficial ownership of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, have filed an amended Schedule 13G.
• As of June 30, 2026, the Reporting Persons collectively hold 0 shares of Quince Therapeutics, Inc. common stock.
• This represents 0.00% of the class of securities outstanding.
• The filing indicates no sole or shared voting power or dispositive power over any shares.
• Nantahala Capital Management, LLC is identified as an investment adviser, and Messrs. Harkey and Mack are identified as control persons of Nantahala.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment filing due to the complete divestment or lack of any beneficial ownership reported by Nantahala Capital Management, LLC and its principals.

Negatives

• Complete divestment or lack of any beneficial ownership reported by Nantahala Capital Management, LLC and its principals.
• The filing indicates zero shares beneficially owned, zero sole voting power, zero shared voting power, zero sole dispositive power, and zero shared dispositive power.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing typically indicates a passive investment stake. The complete absence of beneficial ownership (0.00%) suggests a significant change in Nantahala Capital Management's position relative to Quince Therapeutics, potentially indicating a full exit from any investment or a correction of prior filings.

Stakeholder Impact

• Shareholders may note the complete absence of a significant investment firm's stake, which could influence market perception of institutional interest in Quince Therapeutics.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Investment Adviser, Quince Therapeutics, Nantahala Capital Management